M&T Bank Corp lifted its holdings in shares of Supernus Pharmaceuticals Inc (NASDAQ:SUPN) by 59.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 10,568 shares of the specialty pharmaceutical company’s stock after buying an additional 3,931 shares during the quarter. M&T Bank Corp’s holdings in Supernus Pharmaceuticals were worth $422,000 at the end of the most recent quarter.
Several other large investors have also modified their holdings of the company. Teacher Retirement System of Texas acquired a new stake in shares of Supernus Pharmaceuticals during the 4th quarter worth approximately $695,000. Essex Investment Management Co. LLC grew its position in shares of Supernus Pharmaceuticals by 3.0% during the 4th quarter. Essex Investment Management Co. LLC now owns 65,161 shares of the specialty pharmaceutical company’s stock worth $2,597,000 after buying an additional 1,917 shares during the period. Stephens Investment Management Group LLC acquired a new stake in shares of Supernus Pharmaceuticals during the 4th quarter worth approximately $7,316,000. Alps Advisors Inc. boosted its stake in Supernus Pharmaceuticals by 8.6% during the 4th quarter. Alps Advisors Inc. now owns 66,538 shares of the specialty pharmaceutical company’s stock worth $2,652,000 after acquiring an additional 5,263 shares during the last quarter. Finally, Public Employees Retirement Association of Colorado bought a new position in Supernus Pharmaceuticals during the 4th quarter worth approximately $188,000. Institutional investors own 98.37% of the company’s stock.
Supernus Pharmaceuticals Inc (NASDAQ:SUPN) opened at $38.45 on Friday. Supernus Pharmaceuticals Inc has a one year low of $24.65 and a one year high of $50.04. The firm has a market cap of $1,970.00, a P/E ratio of 34.95 and a beta of 1.08.
Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its quarterly earnings results on Monday, November 6th. The specialty pharmaceutical company reported $0.29 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.27 by $0.02. Supernus Pharmaceuticals had a net margin of 20.98% and a return on equity of 26.37%. The firm had revenue of $80.40 million for the quarter, compared to analyst estimates of $78.74 million. The company’s revenue was up 41.5% on a year-over-year basis. equities analysts anticipate that Supernus Pharmaceuticals Inc will post 1.07 earnings per share for the current year.
In other Supernus Pharmaceuticals news, VP Padmanabh P. Bhatt sold 20,000 shares of Supernus Pharmaceuticals stock in a transaction that occurred on Wednesday, January 17th. The shares were sold at an average price of $44.98, for a total value of $899,600.00. Following the transaction, the vice president now owns 32,500 shares of the company’s stock, valued at $1,461,850. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Victor Vaughn sold 55,000 shares of Supernus Pharmaceuticals stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $40.11, for a total transaction of $2,206,050.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 165,750 shares of company stock worth $7,133,973. Insiders own 6.70% of the company’s stock.
Several research analysts recently weighed in on SUPN shares. BidaskClub lowered shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, February 1st. Zacks Investment Research raised shares of Supernus Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $47.00 price objective on the stock in a research note on Wednesday, November 8th. ValuEngine lowered shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, December 1st. B. Riley lifted their price objective on shares of Supernus Pharmaceuticals from $50.00 to $54.00 and gave the stock a “buy” rating in a research note on Thursday, December 28th. Finally, Piper Jaffray Companies set a $41.00 price objective on shares of Supernus Pharmaceuticals and gave the stock a “hold” rating in a research note on Sunday, October 29th. Four research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $51.36.
ILLEGAL ACTIVITY NOTICE: “M&T Bank Corp Has $422,000 Stake in Supernus Pharmaceuticals Inc (SUPN)” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/02/23/mt-bank-corp-has-422000-stake-in-supernus-pharmaceuticals-inc-supn.html.
About Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.
Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.